Preamble
This volume is based on a symposium held in 1969; there was a second symposium six years later published with the same title (see no. (34) below).

Aims
This book is aimed at students, new medical recruits in the pharmaceutical industry and clinicians involved in the assessment of drugs. It is based on a symposium organized by the Association of Medical Advisers in the Pharmaceutical Industry which was held at the Royal College of Physicians, London in February 1969. Members of our Association have felt for some time that despite the availability of a number of excellent texts on statistics and clinical trial methodology, there is a need for a simple but practical guide to clinical trials. The book is in two parts. The first deals with the principles and practice of clinical trials. The second part presents a number of examples of how the principles and practice can be applied (Preface, page vii).

Contents (xii+254 pages)
Foreword (ML Rosenheim)
Preface (EL Harris, JD Fitzgerald)
Chairmen
List of contributors
Part I: Principles and practice
  Historical aspects of drug evaluation (HJCJ L’Etang)
  Natural history of a typical drug (EL Harris)
  The phases of a clinical trial (EL Harris)
  Clinical pharmacology (CC Downie)
  Ethical aspects of clinical trials (EM Glaser)
  Legal considerations in drug evaluation (DR Chambers)
  Information retrieval (P Wade)
  Initial preparation for clinical trials (JAL Gorringe)
  Preliminary design: the ideal clinical trial (DM Burley)
  Statistical consideration in the design of clinical trials (C Maxwell)
  Clinical trials: practical and commercial considerations (TB Binns)
  The practical considerations of setting up a clinical trial (JG Domenet)
  The mechanics of the clinical trial (AW Galbraith)
  Statistical analysis of clinical trial results (JJ Grimshaw)
  The clinician’s interpretation of trial results (EL Harris, JD Fitzgerald)
  Report writing and publications (JA Waycott)
  The role of the medical adviser in drug evaluation (JD Fitzgerald).
Part II: Practical application
  Cardiovascular drug evaluation (1): Hypertension (WI Cranston)
  Cardiovascular drug evaluation (2): The assessment of anti-anginal drugs
(GE Sowton, JD Fitzgerald)
The evaluation of lipid lowering agents (JD Fitzgerald)
Evaluation of chemotherapeutic drugs in leukaemia and the reticuloses (JS Malpas)
Evaluation of psychotropic drugs (1): In schizophrenia (GR Daniel)
Evaluation of psychotropic drugs (2): Depression, Part I – 1959 (M Shepherd)
Evaluation of psychotropic drugs (2): Depression, Part II – 1969 (M Shepherd)
Evaluation of psychotropic drugs (3): Sedatives (M Hamilton)
How to improve at clinical trials (CRB Boyce)
How to improve at clinical trials: searching for the snags (JF Dunne)
Controlled trials to detect efficacy and toxicity: training to meet tomorrow’s needs (DW Vere)

Index

Authors

The Editors are EL Harris MB, BCh, MRCP, MRCP (Ed) (Senior Medical Officer, Committee on Safety of Drugs), and JD Fitzgerald MB, BCh, BSc, MRCP(Ed) (Research Department, ICI Pharmaceuticals Division, Department of Cardiology, Manchester Royal Infirmary, Manchester, England). The foreword is written by Sir Max Rosenheim KBE, MD, FRCP (Professor of Medicine, University of London, Director of Medical Unit, University College Hospital, and President of the Royal College of Physicians, London). The other chairmen and contributors are TB Binns FRCP, MRCP, DCH (Director of Clinical Resaerch, CIBA Laboratories Ltd); DM Burley MB, BCh, MRCS (Medical Department, CIBA Laboratories Ltd); DR Chambers MB, DRCOG, LLB (Head of Department of Clinical Investigation, Hoechst Pharmaceuticals Ltd); Dr RF Crampton MB, PhD, FIBiol (Director of the British Industrial Biological Research Association); WI Cranston MD, FRCP (Professor of Medicine, St Thomas’s Hospital, London); GR Daniel MB, BA (Medical Director, ER Squibb & Sons Ltd); JG Domenet MB, ChB (Medical Department, Imperial Chemical Industries Ltd); JF Dunne MB, BSc (Lecturer, Department of Pharmacology & Therapeutics, London Hospital Medical College); AW Galbraith MB, DRCOG, DCH (Medical Department, Geigy (UK) Ltd); EM Glaser MD, MRCP, PhD, FIBiol (Director of Research and Development, Riker Laboratories); JAL Gorringe MD, MRCPE (Director of Clinical Investiagtion, Parke Davis & Co); JJ Grimshaw BSc, FIS (Head of Statistics and Management Services, Beecham Research Laboratories); Professor M Hamilton MD, MRCP, DPM (Nuffield Professor of Psychiatry, University of Leeds); CRB Joyce MA, BSc, PhD (Reader in Pharmacology, The London Hospital); HJCJ L’Etang BM, BA, DIH (Medical Department, John Wyeth & Brother Ltd); Professor W Linford Rees MD, FRCP, DPM (Department of Psychological Medicine, St Bartholomew’s Hospital, London); JS Malpas DPhil, MRCP (Senior Lecturer in Medicine, St Bartholomew’s Hospital and Consultant Physician, St Leonard’s Hospital, London); Cyril Maxwell MB, ChB (Medical Department, Geigy (UK) Ltd); M Shepherd DM, DPH, MRCP (Professor of Epidemiological Psychiatry, Institute of Psychiatry, University of London); GE Sowton MD, MRCP (Assistant Director, Institute of Cardiology); DW Vere MD, MRCP (Consultant Physician and Senior Lecturer, The London Hospital); P Wade (Senior Librarian, Royal Society of Medicine); and, JA Waycott MRCP, DCH (Medical Department, Imperial Chemical Industries Ltd).